Nutra Pharma Corp (NPHC) 0.1850 $NPHC
SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53
ACCESSWIRE - Fri Jul 10, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 10, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nutra Pharma Corporation (OTC: NPHC) with a Price Target of $0.53.
Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services
Marketwired - Tue Jun 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in its strategies for maximizing shareholder value through its full scope of investment banking services.
Nutra Pharma enters into facility and personnel sharing agreement with Nationwide Laboratory Services
M2 - Wed Jun 10, 3:23AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) revealed on Tuesday the execution of a facility and personnel sharing agreement with Nationwide Laboratory Services.
Nutra Pharma Announces Collaboration With Nationwide Laboratories
Marketwired - Tue Jun 09, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc.
Nutra Pharma Announces Orphan Drug Applications for RPI-78M
Marketwired - Tue May 26, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Medical Strategy Consultants, LLC to aid the company in the filing of Orphan Drug applications with the U.S. Food and Drug Administration ("FDA"
. The first application under development is for the treatment of Pediatric Multiple Sclerosis with the Company's lead drug candidate, RPI-78M.
Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
Marketwired - Thu May 14, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin(R) for marketing and distribution in Canada.
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
Marketwired - Thu Apr 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Marketwired - Wed Apr 22, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Marketwired - Wed Apr 15, 7:30AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin(R) through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin(R) in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.
Nutra Pharma Announces Distribution of Nyloxin(R) to India
Marketwired - Thu Feb 05, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have shipped their initial test orders of their Over-the-Counter pain drug, Nyloxin(R), to S.Zhaveri Pharmakem for distribution throughout India.
Nutra Pharma Announces Addition of Keith Gordon, DVM to the Company's Medical Advisory Board
Marketwired - Tue Jan 20, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have added Keith Gordon, DVM as their first Veterinarian to join the Company's Medical Advisory Board. The addition of Dr. Gordon comes just a few weeks after the successful launch of Nutra Pharma's newest product, Pet Pain-Away for the treatment of chronic pain in companion animals.
Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
Marketwired - Wed Dec 17, 7:30AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away(TM). The Company also announced that they have begun shipping and many distributors have already received their first orders.
Nutra Pharma Letter to Shareholders
Marketwired - Thu Dec 04, 7:31AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
Marketwired - Wed Nov 12, 7:32AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing the recertification of their Plantation, Florida laboratory facilities. This includes manufacturing, research and production space as well as a clean room module. The recertification allows for the continuing production of their over-the-counter (OTC) pain reliever, Nyloxin(R) and their newest product, Pet Pain-Away; a homeopathic treatment for pain in companion animals. The primary purpose of the laboratory updates, calibrations and certification is to allow the company to re-engage in their clinical platform and to begin eventual trials in their drug pipeline with therapeutic agents for MS, HIV and AMN.
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
Marketwire - Thu Aug 21, 7:30AM CDT
Nutra Pharma Corp (OTC: NPHC)
BUYINS.NET Issues Nutra Pharma (NPHC) SqueezeTrigger Report
M2 - Thu Aug 21, 7:02AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTC: NPHC) after releasing the latest short sale data through August 18, 2014. The total aggregate number of shares shorted since August 2009 is approximately 547 million shares. Approximately 32.11% of daily trading volume is short selling. The SqueezeTrigger price for all NPHC shares shorted is $.08. A short squeeze is expected to begin when NPHC closes above the $.08 SqueezeTrigger price.
Nutra Pharma Provides Nyloxin(R) Marketing Updates
Marketwire - Tue Aug 19, 7:02AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin(R). Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.
Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Aug 19, 6:00AM CDT
Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin(R). These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.
SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53
ACCESSWIRE - Fri Jul 10, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 10, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nutra Pharma Corporation (OTC: NPHC) with a Price Target of $0.53.
Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services
Marketwired - Tue Jun 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in its strategies for maximizing shareholder value through its full scope of investment banking services.
Nutra Pharma enters into facility and personnel sharing agreement with Nationwide Laboratory Services
M2 - Wed Jun 10, 3:23AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) revealed on Tuesday the execution of a facility and personnel sharing agreement with Nationwide Laboratory Services.
Nutra Pharma Announces Collaboration With Nationwide Laboratories
Marketwired - Tue Jun 09, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc.
Nutra Pharma Announces Orphan Drug Applications for RPI-78M
Marketwired - Tue May 26, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Medical Strategy Consultants, LLC to aid the company in the filing of Orphan Drug applications with the U.S. Food and Drug Administration ("FDA"
. The first application under development is for the treatment of Pediatric Multiple Sclerosis with the Company's lead drug candidate, RPI-78M. Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
Marketwired - Thu May 14, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin(R) for marketing and distribution in Canada.
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
Marketwired - Thu Apr 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Marketwired - Wed Apr 22, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Marketwired - Wed Apr 15, 7:30AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin(R) through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin(R) in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.
Nutra Pharma Announces Distribution of Nyloxin(R) to India
Marketwired - Thu Feb 05, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have shipped their initial test orders of their Over-the-Counter pain drug, Nyloxin(R), to S.Zhaveri Pharmakem for distribution throughout India.
Nutra Pharma Announces Addition of Keith Gordon, DVM to the Company's Medical Advisory Board
Marketwired - Tue Jan 20, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have added Keith Gordon, DVM as their first Veterinarian to join the Company's Medical Advisory Board. The addition of Dr. Gordon comes just a few weeks after the successful launch of Nutra Pharma's newest product, Pet Pain-Away for the treatment of chronic pain in companion animals.
Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
Marketwired - Wed Dec 17, 7:30AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away(TM). The Company also announced that they have begun shipping and many distributors have already received their first orders.
Nutra Pharma Letter to Shareholders
Marketwired - Thu Dec 04, 7:31AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
Marketwired - Wed Nov 12, 7:32AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing the recertification of their Plantation, Florida laboratory facilities. This includes manufacturing, research and production space as well as a clean room module. The recertification allows for the continuing production of their over-the-counter (OTC) pain reliever, Nyloxin(R) and their newest product, Pet Pain-Away; a homeopathic treatment for pain in companion animals. The primary purpose of the laboratory updates, calibrations and certification is to allow the company to re-engage in their clinical platform and to begin eventual trials in their drug pipeline with therapeutic agents for MS, HIV and AMN.
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
Marketwire - Thu Aug 21, 7:30AM CDT
Nutra Pharma Corp (OTC: NPHC)
BUYINS.NET Issues Nutra Pharma (NPHC) SqueezeTrigger Report
M2 - Thu Aug 21, 7:02AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTC: NPHC) after releasing the latest short sale data through August 18, 2014. The total aggregate number of shares shorted since August 2009 is approximately 547 million shares. Approximately 32.11% of daily trading volume is short selling. The SqueezeTrigger price for all NPHC shares shorted is $.08. A short squeeze is expected to begin when NPHC closes above the $.08 SqueezeTrigger price.
Nutra Pharma Provides Nyloxin(R) Marketing Updates
Marketwire - Tue Aug 19, 7:02AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin(R). Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.
Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Aug 19, 6:00AM CDT
Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin(R). These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.
